New fibromyalgia treatment medicinal products
DOI:
https://doi.org/10.33448/rsd-v9i3.2308Keywords:
Medicines; Treatment; Fibromyalgia.Abstract
Fibromyalgia is a syndrome that affects about 15% of patients, which manifests itself through pain throughout the body, especially in the muscles, bringing unrepaired muscle fatigue and sleep. The best strategy for managing fibromyalgia is to use a multidisciplinary approach to treatment using pharmacological and non-pharmacological interventions. This article aimed to address the new drugs for the treatment of fibromyalgia through a scientific and technological review in search of patents. The methodology used was a qualitative scientific review of the literature, consisting in the cataloging of data contained in electronic files. As inclusion criteria were considered the articles published between 2014 and 2019 that include the research descriptors, available in full on the internet with database Scielo, Bvs e Medline. Ten articles were cataloged that met the proposed objectives for their insertion in the present study. It was sought in the international network of patents and patent findings in the last 5 years with drugs to treat fibromyalgia. Fibromyalgia is a condition that affects a good part of the population, its treatment is quite complex because there are several drug classes. It can be inferred that new drugs are being studied every day to be used and contain fewer adverse effects in individuals with fibromyalgia.
References
Carbonario, F (2017). Efeitos de um programa fisioterapêutico na melhora da sintomatologia e qualidade de vida de pacientes com fibromialgia [dissertação de mestrado]. São Paulo: Faculdade de Medicina, Universidade de São Paulo.
Carville, SF; Arendt-Nielsen, S; Bliddal, H (2008). EULAR evidence-based recommendations for the management of fibromyalgia syndrome.Ann RheumDis.
De Oliveira Júnior, JO; De Almeida, MB (2018). The current treatment of ffbromyalgia. Br J Pain. São Paulo, , 1.3: 255-62.
Fideles, Alcântara-Neto (2015). Recomendação farmacêutica intensivas. Revista Brasalileira Terapia Intensiva.
Jo, MJ; Yi, HJ; Hwang SG (2019). Medicamento para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associado composição farmacêutica, e, uso de um composto carbamato. SK BIOPHARMACEUTICALS CO., LTD(KR). BR11201073553 1 A2.
Kia, S; Choy, E (2017). Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology. Biomedicines.;5(2):20.
Knudsen, HD (2016). milkweed seed oil administered to animals. Patent Application Publication. Ogallala, NE.
Lucindo J. Quintans-júnior (2017). Nanoemulsion Thermoreversible Pluronic F127-Based Hydrogel Containing Hyptis pectinata (Lamiaceae) Leaf Essential Oil Produced a Lasting Anti-hyperalgesic Effect in Chronic Noninflammatory Widespread Pain in Mice. Mol Neurobiol. Springer Science+Business Media New York.
Malloy, EM (2016). Compositions and methods for treatment of fibromyalgia. WO 2016196274 A1.
Mendes, RR (2016). Papel dos recursos eletrotermofototerápicos no tratamento da fibromialgia. Belo Horizonte.
Moore, RA (2012). et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Databaseof Systematic Reviews, n. 12.
Organização Mundial de Saúde. (2018). Envelhecimento ativo: uma política de saúde. Tradução Suzana Gontijo. Brasília: Organização Pan- Americana de Saúde.
Porto, EF et al (2015). Efeito da hidrocinesioterapia sobre qualidade de vida, capacidade funcional e qualidade do sono em pacientes com fibromialgia. Revista. Brasileira. Reumatologia, São Paulo, p. 846-857.
Pridgen WL (2015). Valacclovrand meloxcam combination therapy for functional somatic syndromies. Patent Application Publication. Pub. No.: US 2013/0203742 A1. Pub. Date: Aug. 8.
Ribeiro, FN (2016). Fibromialgia: o corpo, a mente e o estigma.
RiccI, NA; Dias, CNK; Driusso, PA (2015). Utilização dos recursos eletrotermofototerapêuticos no tratamento da síndrome da fibromialgia: uma revisão sistemática. Revista Brasileira de fisioterapia, São Carlos, v. 14, n. 1, Fev.
Savegnago; Casaril, AM; Domingues, M; Fronza, M; Vieira, BM; Lenardão, EJ; Begnini, KR; Seixas, FK; Collares, TV; Perin, G; Alves, DS; Jacob, RG (16/11/2016). Utilização do 3-(4-clorofenilselenil-1-metil-1h-indol como uma molécula antidepressiva. C07D 345/00 (1974.07), A61P 25/24 (2000.01).
Tadamasa, A; Katsuhiko, I; Naoki, I; Shuji, I; Yasuhiro, M (10/04/2018). Derivado da amina cíclica ou de um sal farmacologicamente aceitável, como medicamentos analgésicos, terapêuticos para dor neuropática e terapêuticos para síndrome da fibromialgia. Publicação de BR112017017859A2.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
